dbGaP

application/xml

ftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/release_notes/Release_Notes.phs001391.OncoArray_ProstateCancer.v1.p1.MULTI.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c8.DS-PC.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c1.GRU.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c4.PC-MDS-NOCTRL.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c27.DS-CA-MDS.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c24.HMB-PUB.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c2.DS-PC-PUB-MDS.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c25.DS-CA-PUB.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c22.MHNSI-MDS.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c18.DS-PCP.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c15.DS-CA-NPU.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c9.HMB.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c28.EPIMEDCA.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c23.PC-RITPC.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c12.DS-BCEMOPCA-NPU-MDS.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c5.HMB-NPU.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c14.DS-CA-MDS-GSO.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c13.DS-CA.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c6.DS-CHDSAD-MDS.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c20.GRU-NPU.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c19.GRU-IRB.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/Study_Report.phs001391.OncoArray_ProstateCancer.v1.p1.MULTI.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c3.DS-PC-MDS.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c17.DS-PC-MDS-GSO.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c16.DS-CA-NPU-GSO.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c7.HMB-PUB-NPU.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c11.CHRONIC.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/manifest/manifest_phs001391.OncoArray_ProstateCancer.v1.p1.c10.CADM.pdfftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007078.v1.OncoArray_Prostate_Cancer_Subject.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007080.v1.OncoArray_Prostate_Cancer_Subject_Phenotypes.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007081.v1.OncoArray_Prostate_Cancer_Sample_Attributes.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007079.v1.p1.OncoArray_Prostate_Cancer_Sample.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007081.v1.p1.OncoArray_Prostate_Cancer_Sample_Attributes.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007078.v1.p1.OncoArray_Prostate_Cancer_Subject.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007080.v1.p1.OncoArray_Prostate_Cancer_Subject_Phenotypes.var_report.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/GapExchange_phs001391.v1.p1.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/phs001391.v1.pht007079.v1.OncoArray_Prostate_Cancer_Sample.data_dict.xmlftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/varreports_v3.xslftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/pheno_variable_summaries/datadict_v2.xslftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs001391/phs001391.v1.p1/dbGaPEx2.1.5.xsdprimaryOK200GenomicCase-Controlhereditary prostate cancer, cancer of the prostate, Prostatic Neoplasm, Cancer of the Prostate, Prostate Neoplasms, Neoplasms, Prostatic Cancer, Neoplasm, Prostatic Cancers, Prostatic, familial, prostate cancer, PC, NOS, Cancers, Cancer of Prostate, Prostate Cancer, cancer of prostate, Prostate, Prostate Neoplasm, Cancer, Prostate Cancers.https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391Funding Source - U19 CA148537 - National Institute of Health, Bethesda, MD, USAPrincipal Investigator - Christopher Haiman - The University of Southern California, Los Angeles, CA, USAdbGaPduplication of the halluces and polydactyly, SPI3, FBgn0003149, SCYA18, Ghrfr, artificial sequence, Materials, Unspecified disorder of immune mechanism, Kinship, DmNa[[v]]1, dUNC-13, Smc3, Case Referent Studies, Addresses, fatal X-linked, mental retardation, Mutamycin, Survey Methods, FAS1, FAS2, DmelCG9774, SmcD, APO-1, A2AP, ter, megakaryocytes, cdc, anon-3B1.2, neurodegeneration with brain iron accumulation caused by mutation in PLA2G6, Summary Report, Associations, 1, 2, Percutaneous, 3, 6, LARS1, International Agency, Laboratory Research, CG9390, 2810441M03Rik, Angers, like-acetylglucosaminyltransferase, Data Collection, myocardial infarction (disease), Diary, hsp-27, NKR-P1A, Case Base Studies, CE5B3, Centers for Disease Control and Prevention, Xcat, Boys, Y, diffuse cerebral degeneration in infancy, Workshop, Dm Arm, G(o)alpha47A, Social, 1D4, goku, DmelCG9748, geographical area, Indemnity, Cancer of the Prostate, Ach, BEL, acetyl-CoA synthase activity, FASD, Ell1, Acs, cleft lip and/or palate with mucous cysts of lower lip, Red, mDRS-1, mDRS-2, l(1)W3b, l(2)SH1599, Smcd, hsp 27, PGAD, X-ray therapy, Infarct, l(1)W3, AnxB9, syndromic 18, Data Set, Infarcts, Endowment, Vnd, Dimerization cofactor of HNF1, gov, Endoluminal Repairs, Longterm Effect, Racial, SORB1, CG3665, COUNTRY, Normalcy, Emc, CG1007, PGDH, Republic of the Congo, par, pas, Experimental, Benign, Financial, DEL cells, type 1 DC, European, mKIAA0609, Algorithm, Hmg1, Lobe of mammary gland, Pcnt2, margin of safety, DDB1, Donors, l(1)14Da, DmelCG5363, Human Subjects, Research and Development, A2HS, immune system disorder, death rate, l(1)ESHS48, N-WASP-binding protein, Adenomatosis, Benign Neoplasms, Rhk, Records as Topic, whole genome, Laboratory Marker, National Cancer Institute, Educational Activities, late-onset, Malignant Neoplasms, ZNF463, retraction syndrome, Black Americans, CG10523, sbl-1, Artificial Insemination, Report, SCYA28, HSPC192, Literacy Programs, multiple, betacat, TakR86C, historical notes, 1110008J03Rik, ds DNA, Personal Identification System, Cdk-1, Preventive Medicine and Public Health, l(4)ry16, DmelCG32810, Social Epidemiologies, American Cancer, Community, Disorder of the immune mechanism NOS, prostatic hyperplasia, INAD1, refractory, limb digit, hypoglossal nerve [XII], atypia, AnxB10, lifespan, localised, G[[o]]alpha, dendritic reticular cell, Endoluminal Repair, region or site annotation, Neoplasms, developmental stage, shak-B, DGalpha[[o]], TNFRSF6, Aid, Kal3, cll, Deoxyribonucleic Acid, Bradeion beta, capping protein, C86297, DmelCG7507, hypotonia, Baseline Surveys, SH3 domain protein 5, Screening, Nested Case-Control, Continental Population Group, Randomized Response Techniques, CG4561, Financing, cranial nerve XII, Dhc64c, ACLS, Magen David Adom, Upper Arm, l(2)k12101, family history of malignant neoplasm, School-Age Populations, Crete, hypoglossal XII nerve, Unc-13, 5q syndrome, American, DmelCG4466, anatomical systems, PCAP, A proliferation-inducing ligand, Clinical, Academic, 4-alpha-hydroxy-tetrahydropterin dehydratase, DmelCG8827, Placental thrombin inhibitor, PCBD, Investigators, prevalence, Diagnoses and Examinations, Respondent, Population, Lpla2, Questionnaires and Surveys, Tobacco Smokers, ptuf1, BMH, AcCoAs, Neoplasias, l(1)R-9-29, ance, Health Service, drugs, nj156, anatomical unit, Grants, 65K, DmelCG18572, body organ, AnCE, Training Programs, Population Registers, Sonic Radiations, Non-Tobacco Products, Dcdc2, SPS1, Heterologous, Acas1, AI196731, findings, Malignant Neoplasm, Targeted Radiation Therapies, 3110013H01Rik, lab, Serum Markers, prad, Kal-3, CG9802, Joubert syndrome 12, CG6775, AGL63, CG5441, Phenylalanine hydroxylase-stimulating protein, defective, F28K20.7, Synaptosomal-associated 25 kDa protein, DmNav1, CD257, CD256, Cytoplasmic antiproteinase, disease or disorder of immune system, cpn, SCCA-2, dACS, Investigative Medicine, hypoglossal XII, 263/16, Public, l(1)VA208, l(1)G0500, chemical analysis, Prostatic Cancer, Research Reports, Long Term Effects, Urine Collections, 9530001P15Rik, with Hutchinsonian teeth, Rok, Public Health Service (U.S.), collecting duct carcinoma of the kidney, condition, IMPACT, supply and distribution, Death, LCP3, BPH, Caucasoid, Ann, Artificial, DmelCG7933, ROCK1, Cardiovascular, Cell division control-related protein 2, DmelCG7937, Lobe of breast, acetyl-coenzyme A synthase activity, Nested Case-Control Study, School Age Populations, 2-methylacyl-CoA racemase, REDK, Dpark, disorder of immune system, Basement membrane-associated chondroitin proteoglycan, APRIL, National Program of Cancer Registries, Medical Schools, 4732433M03Rik, ACSA, DRORUD, Bellini’s duct carcinoma, sequestering, Jan, absence of corpus callosum with unusual facial appearance, Neoplasia, formerly, CG10120, Dhsp27, Lower Urinary Tract Symptom, DmelCG5730, Networks, l(1)G0410, pepper syndrome, Biological Markers, Viral Marker, Forestland, Breasts, supply, Afro American, ADE2H1, 232, SCKL4, LACS 1, Cardiac Death, FamilyHistory, D8Ertd387e, Literacy Program, Suprapubic, refractory macrocytic anaemia due to 5q deletion, BSP, element, CG11478, School-Age, primary red cell aplasia, Techniques, Facl2, Nkd, dsps1, 2310045K21Rik, SUP, APO1, Familiar breast and Ovarian cancer syndrome, Population Group, Nkr, KEN, 6-piperidinedione, (2Z)-but-2-enedioate, Autoimmune, Arm, BRCA2 Genes, Stock, BSp, Funds, Group, human disease, DmelCG2684, DmelCG2204, GORDITA, Immune System and Related Disorders, Athletics, Statistic, CG12352, hCDCREL-2, l(1)TH73, Mmip1, antineoplaston-A10, retention, Diaries, DCoH, anon-EST:Posey121, CG5363, dCdk1, disease management, Services, R-9-29, Rectal Palpations, Biopsy, EPD1, TNFSF20, jan A, l(1)EA142, Federal, cancer of the prostate, late onset Parkinson disease, THPH5, CG9774, NAT13, DmelCG10120, IRF-1, gyltl1b-b, THPH6, Financial Activity, AI853657, cyclase-associated protein, lit, Double-Stranded, somatic, familial endocrine, nj-156, DmelCG2650, Task Forces, 27K, Research Subject, prm, hereditary prostate carcinoma, Areas, DURS, Near-Death Experience, UNC-13-B, Serinus canarius, 2610511I09Rik, ZNF912, Postmortem Diagnosis, KIAA0609, GAT, Electronic Health Records, familial prostate carcinoma, Christmas Island (Australia), Private Practices, RITA, Hsp 27, Postmortem Diagnoses, Acquired, Clinical Investigator, histopathology, Collection Methods, Review, N-(2, anon-WO03040301.224, susceptibility to, Dignity, CG9748, APT1, Smoker, radioisotope therapy, DmSMC3/Cap, PAST1, Dimerization cofactor of hepatocyte nuclear factor 1-alpha, small hsp locus 67B, Matched Case-Control, MYOCARDIAL INFARCTION, Saint Pierre and Miquelon, Treatments, early, NS21, disease, 2.3.1.-, SYNTHETIC CONSTRUCT sequences, Needle Biopsies, dROK, NKD12, PGHS-1, International Federation of Red Cross and Red Crescent Societies, anon-48Ac, Endowments, Duane anomaly, anon-WO0118547.278, PAP-A, RACE, Registered Nurse, Fas, prostate, PI-10, Puncture, PI-12, Prostate, prostata, Gruppe, acute myocardial infarction, l(1)G0014, prostate specific antigen levels, F12K11.4, Galpha[[o]], DJ885L7.4.1, DmelCG1775, Prostate Neoplasms, Clinical Markers, PLAN, PLAP, Training, l(3)64Ca, NAT5P, Network, dgoalpha, Malignant, Ximpact, Case-Comparison Studies, mucoepidermoid tumors, EG:155E2.1, DmelCG9252, Gyltl1a, Surrogate Markers, Drok, mPM, veiled cell, mucoepidermoid, Myocardial Infarction, EPIP, Acetate--CoA ligase, PSPBP, Athletic, Data Collection Method, Country, FETUA, lod, l34Eb, methods, DFNB91, l(1)G0032, teaching, P-30 antigen, Educational Activity, CG15466, l(3)j4E11, benign prostatic hyperplasia, LLPL, YARS, Victoria <moths>, 3110009L02Rik, Administration, l(1)G0048, Canary, CDK1/CDC2, DmelCG12352, DmelCG3924, lpr, NAT5, Nav1.6, Randomized Response Technique, Long-Term Effect, l(2)34Eb, Governmental Commissions, Immunologic Marker, PP1131, CG15451, HHT1, incidence, TCF1, Controlled, SDK3, DYRK5, Repeated Rounds of Survey, Suprapubic Prostatectomy, VIP54, KARAK syndrome, Data Collection Methods, Medical Specialty, MYOCARDIAL, Electronic Health Record, Multiple Endocrine Neoplasia, Tobacco Smoker, Sport, anon-WO0140519.69, Goalpha, Hospital, Brustdruese, Woman, Anx B9, HEL-S-6, OK/SW-cl.81, group, CG1404, Rock, AW112078, TC4, count in organism, 6.2.1.1, Priority, p-Dichlorbenzol, CAD, PGHS1, GLI3-190, Health Records, l(1)1Bf, Mass Screenings, Centers for Disease Control and Prevention (U.S.), Research Activities, Registered Nurses, Liquidobacterium, Health Care, 3-PGDH, CAP, Gm389, Serinus, radiation therapy, DmelCG6172, BG02184, Ethiopian, Investigational, drs-2, Random selection by shearing, drs-1, San, Response Techniques, l(1)G0075, Retropubic, Digital, mitochondrial DNA depletion syndrome 4A (Alpers type), operative therapy, Stilling-Turk-Duane syndrome, CG7171, HUR7, Review Committee, Case-Base, anon-35Fa, BcDNA:LD24380, l(1)19Eb, arc degree, Center for Disease Control, MOX2, Age symptoms begin, Population Groups, sample population, MOX1, National Center for Advancing Translational Sciences, anxX, Hox11-311, l(3)10631, ETX1, PHAPI2, anon-35Fc, Data, acetate:CoA ligase (AMP-forming), 38B.5, ADE2, Gsp1, Ethnicity, SCCA1, Multiple endocrine adenomatosis, G-oalpha47a, SCCA2, l(1)G0081, Cardiovascular Strokes, forelimb digit, CG32810, Field Report, Scl, Historical, CDC, NK-2, dYARS, degree (angle), dei, HSHUR7SEQ, del, Laboratory, SMC3, FON1, Design, Practices, CG1321, National Government, PCOX1, growth and development, Progress Reports, Diagnosis, PPS1, Scholarship, prevention, Long Term, General Internal, SeS, Other specified disorders of the immune mechanism (disorder), Wasbp, Mutations, Ade2h1, Personal, Alpers diffuse Degeneration of cerebral Grey matter with hepatic cirrhosis, pass, unspecified, Generic Action, due to 5Q deletion, Other specified disorders involving the immune mechanism, Dm-SelD, Medical Transcriptions, Solo Practice, Method, Case Referrent Studies, nervi hypoglossalis, Commissions, AGAMOUS-like 63, African-American, SDR27X1, Research Activity, DCCK1, Specimen Collection, Randomized Response, SMC-3, adult, Nested Case-Control Studies, beta-Cat, MCC1, organ, average, treatment, Multicase, ethnicity, Parkinson disease, acute myocardial infarction (disease), G-oalpha, Genomes, ChIP, dgo, TRDL-1, Intervention Study, Bdr, Matched, PNCA4, composition, 4930479N23, GOA, NTef2, CDLS3, dhc, EG:196F3.2, SNAP-25, R74825, Social Epidemiology, MCAP, chip, Apoptosis-related protein in the TGF-beta signaling pathway, FAS II, Airc, Field Reports, epiphyseal dysplasia, Bel, ELL1, Merkel Cell Carcinoma, GOV, Medicine, Public Hospitals, 4732490P18Rik, stage, Infections and Infestations, hsp27/26, ran-1, Diagnose, Dm cdc2, hereditary breast ovarian cancer, EIEE13, Wiskott-Aldrich syndrome protein-interacting protein, DmRH6, l(2)k04405, Radiation, Bh5, CSA2, Diagnoses, xran, DmelCG4399, ZNF361, Su(b), Radiotherapy, BcDNA:AT12574, Sonic Radiation, PCD, Area, GENA70, University, CG5730, DHC64C, PCN, 0977/09, YSC1, heart attack, Case-Referent Study, Red Crescent, Industrial, CG33979, End Points, training, Ethiopian Wolf, Nonrespondent, Field, School, INSDC_feature:gene, Rexin, Shak-B, human, Puncture Biopsies, International, Grant, Endocrine neoplasia, myocardial, Arts type, Medical Records, Rectal Palpation, Urine Collection, Aspiration Biopsies, Physician, Su(Gl)77, Identification Systems, Primary Healthcare, unc, DmelLcp3, BG:DS02740.11, Dm-NK2, Atlantic canary, CG2684, Ocd, Death Causes, School-Age Population, p-Dichlorobenzene, DmelCG18408, other neoplasm, Collection Method, Mdh-NADP, CG2204, 54 kDa VacA-interacting protein, PSATD, Radiation Treatments, DIP1, Respect, Effects, U4|U6.U5-27K, Aspect, acropodial unit, l(3)L4740, C87498, men syndromes, d-ddb1, SUPERMAN, ZTNF4, NKR-P1, ZTNF2, LARGE1, Bkh, unspecified (disorder), Human, familial prostate cancer, ALPS1A, Attack - heart, Sd-RanGap, DmelCG5203, Pure Red Cell Aplasia, direct RNA-seq, GH14582, ILFS1, PGD, medical examination, Community Survey, Republic of Poland, bHLHc10, disease or disorder, Randomized, lip pit syndrome, Epidemiologies, memA, anon-EST:fe3D10, Acetyl-CoA synthetase, PI-6, Practice, Sound Wave, NKRP1A, Dbd1, MDDGB6, LCP-3, Delilah, Elastic, Deoxyribonucleic acid, FANCS, PHS, PI6, dpk, Acyl-activating enzyme, D8Ertd814e, DmelCG6515, Faeroe Islands, Government, CP3, cdk1, Educational, PIC, PIF, LAB, CG7933, Nkx2, LEURS, Dm SelD, uro, Development and Research, operative procedures, UBOX1, PDCB, CSPG6, PIT, Primary Care, LAR, Biologic, CG7937, Fs(3)Lab, WBSCR5, Individual Health, cg11478, Andr, CPS, Glycoprotein PP63, Pnutl2, mak3, Dm0688, ran10A, COAA, 311, Urine Specimen Collections, Personal Identification Systems, Primary, compositionality, l(2)04405, Records, CG7507, AF3p21, Family Members, DmelCG4795, CN-XII, drs, Arms, cancer diagnosis, Case-Referrent, mda, susceptibility to psoriatic arthritis, Advisory, Elastic Waves, post-mortem, Dynein, RNTLS, Collection, Bph, DmNa[[V]], Biologic Markers, short chain fatty acyl-CoA synthetase activity, CG12678, Semenogelase, United States of America, Tall2, Rectal Examination, DMLCP3, LDB, Surrogate, PLI, Information, Arp2, prophylaxis, PYR1, med, Case-Control Studies, RanGap1, postnatal growth, Chromatin Immunoprecipitation, mem, DUNC-13, CSD, men, 90 kDa SH3 protein interacting with Nck, FLAF2, SH3D5, primary structure of sequence macromolecule, included, upper extremity, male human body, Forestlands, like-glycosyltransferase, Families, ORF1, structure, Sh3d5, Case Control Study, CG4466, prostate cancer, l(1)R-10-14, digenic, epidemics, DmelCG10523, SBP-1, PN4, biopsy, Forest, RAB16, General activity, PI11, ROKalpha/beta, PI10, breast, Myocardial infarction (disorder), CG8827, PI13, Immunodeficiency with predominant T-cell defect, PI12, Health Diary, D1Ucla3, deceased, Activity, Premium, multiple endocrine neoplasia syndrome, Blood, adult stage, Åland Islands, Fasii, acetyl-CoA synthetase activity, DEIH-BOX RNA/DNA HELICASE, Biochemical, PHS1, CG4399, Health Record, Serum, Black American, acetate to acetyl-CoA, glandula mammaria, acrocephalosyndactylia, Speciality, Workshops, Gm48, Racial Group, Forested, Malaya Federation, cg9748, WBSCR15, cytopathology, BROVCA1, AAF30287, Kallikrein-3, Summary Reports, Sarawak, Blood Donor, 4.2.1.96, male, C12orf52, family history of cancer, DROGPAD, EDM1, AAP-S, Phosphoribosylaminoimidazole-succinocarboxamide synthase, Cerebral protein 7, EDM2, 27, EDM3, rangap, 28, Shak B, Deficiency of cell-mediated immunity, COH1, pre-mortem, CBAS4, Governmental Commission, PPS, benign, free, Stroke, CYPIIA5, Sabah, wolf, cdc2Dm, hSAN, Racial Stock, Viral Markers, Pathologies, Therapies, Schinzel type, ms(3)Pneo85A, Premiums, Medicines, DNAn, Family Life Cycles, CXN, 0263/16, somatic mutation, imperforate anus, Mak3p, Nurse, Multifactorial, mamma, Therapy, MIP-4, E330037C19, DJ39G22.4, Surrogate Endpoint, aberrant, AW413978, ano-cerebro-digital syndrome, PubMed, Arts, l(2)SH2 1599, CE5B3 beta, Sounds, inx8, beta-catenin/Arm, ellipse, PSA, anon-WO0172774.145, PCTN2, Case-Referent Studies, Program, infantile neuroaxonal dystrophy/atypical neuroaxonal dystrophy, Screenings, anon-WO0172774.146, acetate thiokinase activity, Cardiovascular Stroke, HCE, MDDGA6, CAP1A, RENBP, Diseases, Specialty, Genetic Materials, Scholarships and Fellowships, laboratory, AIDD, Benign Prostatic Hypertrophy, Adults, acetylglucosaminyltransferase-like 1A, CG13570, Hopes, Canis lupus, SDCCAG7, Caucasians, Populations, Governmental, Fund, PTI, gyltl1b, positional polypeptide feature, Annx, NCI (US), DROK, CAP/Vinexin, mdc1d, Merkel Cell Cancer, common, Nurses, immune dysfunction, canary, Life Cycles, Insurance Medicines, dRok, Duane syndrome, Patient, DmelCG2999, Heart attack, artificial, inherited genetic, Canario raza, Review of Reported Cases, C86676, zTNF4, rexin, Dia-interacting protein 1, LCAT-like lysophospholipase, 2010309L07Rik, Malignant Neoplasms., other disease, human being, H-PAST, Canton and Enderbury Islands, AUTOIMMUNE DISEASE NEC, olfD, 2210017D18Rik, Benign Neoplasm, AMAC1, autosomal dominant, 54 kDa vimentin-interacting protein, United States Centers for Disease Control and Prevention, val, Prkn, dNK-2, Isle of Man, dSMC3, Committees, brachium, refractory macrocytic anemia due to 5q deletion, Baseline, Pterin carbinolamine dehydratase, 5q deletion syndrome, l(3)87Dh, l(3)SG36, Afro-Americans, Medical Research, Prostatic Cancers, Wave, Lysophospholipase 3, mKIAA1296, Survey, Parish Registers, DDB-1, Society, DmelCG8271, Contract, intellectual disability, Prostate Cancers, putative HLA-DR-associated protein I-2, Palpation, ROCK, AMACRD, Woodlands, Genetic, Galpha[[047A]], Malignancy, DRSP, Prostatectomies, LPS, DmelCG13570, U4|U6.U5 tri-snRNP-associated protein 3, multiple endocrine neoplasia, Midway Island, LARGE, Alpers diffuse Degeneration of cerebral Gray matter with hepatic cirrhosis, MSTP057, annexin, Maintenances, G[[o]], cataract dental syndrome, BPFD#36, acrocephalosyndactyly, Mif1, MAB1D4, Mesiodens-cataract syndrome, FAS 11, RANDOM, Case-Control, Merkel Cell Tumor, grupos, Informed, CG6172, clone 1.60, AMACR, Smad4, Targeted Radiotherapy, culture, African unspecified, 0610033N24Rik, Healthcare, l(1)2Bv, Rectal Examinations, span, Sound Waves, DmelCG9579, Galpha[[0]], LRS, CG9252, not elsewhere classified, Governments, SEP4, Canary Islands, DC1, dJ1161H23.1, Historical Aspects, Client, Examination and Diagnoses, Computerized, infantile poliodystrophy, PES-1, drunc13, Review Literature, Organized Financing, group 4, Familial endocrine adenomatosis, ROCK-1, sequence, DD3, Cap, Fas II, Environment, CG1775, late-onset Parkinson disease, Electronic Medical Record, death, acetyl coenzyme A synthetase activity, interdigitating cell, Nested, 3.4.21.77, uracil mismatch repair protein, Transcriptions, Women's Groups, THBS5, operations, Case-Referrent Study, 77H5, cyp26, BG:DS08220.3, Radiation Treatment, Negro, l(3)SG70, CG3924, l(1)G0192, HERP, endemics, FCP-A, Holland, A630082H08Rik, Baseline Survey, F28K20_7, CG18409, DEF, sample collection, CG18408, Service, DEL, Societies, Indexes, SNAP, Modern Man, renin-binding protein, cleft lip/palate with mucous cysts of lower lip, Aspects, ORW1, 1258/16, Prostate Cancer, growth, Urine Specimen, CDCDm, glycosyltransferase-like protein LARGE1, Hunter Carpenter Macdonald syndrome, Centers for Disease Control (U.S.), acetic thiokinase activity, Vapers, nk-2, Radiation Therapies, paradichlorobenzene, Advisory Service, CG32508, CTRCT40, CG30327, Tumor, Tfm, TALL-2, Questionnaire Designs, Medical Specialties, ran, TALL-1, AC, Pathologist, hsp28, Donor Artificial Insemination, hsp27, Para, hsp26, SERA, CENP-V, Abc8, Biological, Survey Methodology, MUCC, Park, Life Cycle, Causes of Death, Nursing, KLK2A1, fas2, Faroe Islands, myd, Fs(3)Hor, East, DHC, DmelCG9999, HACD1, AIRC, Kinship Network, DHO, Chip, Personnel, OFC6, HDC16822, Tissue, Radiotherapies, 7-Amino-9alpha-methoxymitosane, NTAL, COX3, Goa, COX1, YRS, Peanut-like protein 2, 3-((phenylacetyl)amino)-2, LEUPIN, Ab 1D4, CG2999, LACS1, CD, Non-Tobacco Products Smokers, Dunc13, CG10728, DIP, Bsg75C, Cdc2, l(3)61Da, Homo sapiens disease, l(1)LB21, Register, Acyl-CoA synthetase short-chain family member 2, Chondroitin sulfate proteoglycan 6, xCYP26, Primary Health, prostate carcinoma metastatic, Tumors, Forested Area, Prostate Cancer Aggressiveness, PRS-I, screening, SH3P12, Pas, Rectal, Prostates, Multiple endocrine neoplasms, FASTM, Targeted Radiation, early onset of peripheral gangrene, Waves, Epidemiology, SSP29, WISH, e(Pc), Dhc46C, acu, Research Priorities, Case-Base Studies, VWS1, dunc-13, Fs(3)Sz18, YTS, historical aspects, HMG-CoAR, Fs(3)Sz11, LYPLA3, add, late onset Parkinson's disease, 6-dioxo-3-piperidinyl)benzeneacetamide, AMACR_HUMAN, Medical Speciality, KU-MEL-1, Immunodeficiency and Immunosuppression Disorders, Postmortem, Term, Marker, Relative Risks, Pcd, p-chlorophenyl chloride, simple tissue, Ag 72H5, multiple endocrine adenomatosis, African American, NCATS, oligonucleotide random primer, DmelCG7776, Phosphoribosylaminoimidazole carboxylase, Industrial Arts, GLI3FL, Centers for Disease Control, PM/mPM, 2310026N09Rik, Brain protein H5, SRPX1, headpin, 0.9 gene, Infection and Infestation, Immunologic, Solo, International Red Cross and Red Crescent Movement, study protocol, OA-519, cancer of prostate, surveillance, Pdn, dRanGAP, PCNT2, Activities, BRADEION, Fellowship, MDC1D, DmelCG7769, Elastic Wave, 0587/01, Agencies, enr, Dmel_CG12678, Brachiums, Wiskott-Aldrich syndrome protein-binding protein, H5, PCNTB, Surveys, Transluminal, White, GXVPLA2, TNFR6, acetyl-CoA:corrinoid protein O-acetyltransferase activity, (MI), DNA, janus, progressive, BLYS, gp160, UOX, FLORAL DEFECTIVE 10, HSPABP2, hypoglossal nerve tree, Cll, GH05739, hypothalamic hamartoblastoma, DNS, Go, anon-EST:Liang-1.60, (Deoxyribonucleotide)n, MP100, Gray Wolf, LPLA2, psoriatic arthropathy, macrocytic Anemia, number, Multiple endocrine neoplasia, CG4795, SCAR16, Percutaneous Transluminal, Normalcies, HMG-1, ara24, Smokers, Cdhc, infantile, acute chest syndrome in sickle cell disease, Aspiration, Sd-RanGAP, Caucasian, c-Cbl-associated protein, USPHS, Publication, neuronal Degeneration of childhood with liver disease, Dcap, F12K11_4, atypical, unilobular nucleated, Cancer of Prostate, Medical, RGD1306772, Person, aid, MAR, DmelCG2043, Chs1, acetyl-activating enzyme activity, NY-CO-7, Red Wolf, medea, lcp3, Longterm, Dual Data, TNF-related death ligand 1, ANCE, Double Stranded, Phs, DSEP, U.K., BLACK OR AFRICAN AMERICAN, Coh, Nhs1, nerve XII, Medical Record, Study, men syndrome, DmelCG4216, L3, curriculum, OX-2, MCC, Lab, HEL-S-284, ACAS2, DmelCG9907, Prostatic, Chronic, Heart Attack, CG3451, (Deoxyribonucleotide)m, Investigative Reports, Cdk1, Needle Biopsy, Negroes, MCT, DRS, Hsp28, MI - Myocardial infarction, modifier, grupo, Family Research, Women's Group, DNAn+1, 1-O-acylceramide synthase, MDH, disorders, XCYP26A1, CG5203, Cancer Societies, NPCR, bHLHb28, ME, MI, Trdl1, myocardial infarct, Immune Marker, Acoustic, MT, Retropubic Prostatectomy, DAKAP550, Center for Disease Control and Prevention, male prostate, MED, April, Malay Federation, Psat, Population Study, A530094C12Rik, imprinted and ancient gene protein homolog, Munc-13/UNC-13, POOR HOMOLOGOUS SYNAPSIS 1, TyrRS, MEN, Me, DFN2, l(2)k12303, ptf1, Merkle Tumors, ami, DTL, Relative Risk, Training Program, hr025Cl, Pallister-Hall syndrome, Mab77H5, Electronic Medical Records, Digital Rectal, Go-alpha, PRCA, c15, AA591035, ensemble, Ldb, Cancer Society, IMMUNDEF T-CELL DEF NOS, l(2)28-28-12, Committee, Response Technique, ARP2, CG6515, DmelCG33979, renal medullary carcinoma, Myocardial, Medical School, Record, Lds, malignant tumor, PSA measurement, HUNKI, mAB1D4, FASII, DmHSP27, Ns, OU, AVIEF, data collection, Desoxyribonukleinsaeure, PC, Researchers, PD, LEUS, Poliodystrophia cerebri progressiva, syndromic, Mak3, HUNK1, l(2)06955, Relatives, 0.9, PM, E81, ShakB, single-organism developmental process, Strokes, infarction (MI), Registers, THANK, lethal ataxia-deafness-optic atrophy, FasII, Non-Tobacco Products Smoker, African-Americans, Infestations and Infections, Endpoint, jan, dSPS1, PPP1R53, Foundation, Repair, metastatic prostate cancer, Malaya, A10, Laboratory Markers, ranGAP, sampling, Specialities, Fs(3)Laborc, acute chest syndrome, Percutaneous Transluminal Angioplasty, DRhk, l(3)S097074, Nonrespondents, FascII, prevention and control, LAP4, RM, D-DDB1, A 10, Dmcdc2, Cardiac infarction, DEFIC CELL IMMUNITY NOS, Occidental, BRCC1, AW476095, Klk3, Parish, entire life cycle, CG7769, SD, Cyp15a2, U.S., Case Control, LARS, Groups, Super protein, Wolf, SO, arm, dUnc-13, genetic, CG34358, hNAT5, CKb7, DmSMC3, cataract, Immune, Respondents, ARTS, AW046544, varicose-related, Sd, CG7776, tumor, shkB, ICR, hCAP, Long-Term Effects, So, Black Populations, U4|U6.U5 tri-snRNP-associated 27 kDa protein, Acoustic Waves, l(3)12m-137, Specialties, IDD, Commission, organisation, BRCA1, CT28175, BRCA2, D2-2, DmelCG5939, Nursing Personnel, Case-Compeer Studies, Myocardial Infarct, BRCAI, SCML1, white, CDC-NPCR, Biochemical Markers, hypothalamic hamartoblastoma syndrome, Dcoh, Blood Serum, UO, Vaper, results, Psa, (Deoxyribonucleotide)n+m, MMC, l(1)VE769, School Age, Dm vnd, Examinations and Diagnoses, l(3)S010605, RhoK, Individual, Racial Stocks, CG14784, Filiation, digit skeleton, Uo, psoriatic arthritis, W3, Rasl2-8, Federation of Malaya, CG14783, Diagnoses and Examination, l(1)G0234, PGG/HS, Sonic, DRok, Determination of Death, Blacks, p30, l(1)R-10-3, hypoglossal nerve/ root, Advisory Committee, Nationalities, PNDC, Survey Method, l(1)R-10-7, Case-Comparison, race, Biochemical Marker, 4.1.1.21, E(PC), Infarction of heart, SMC3L1, mKIAA1352, CG9999, St. Pierre and Miquelon, AIR carboxylase, Matched Case-Control Studies, Seminin, Mitocin-C, Dual Data Collection, Midway Islands, 2600005K24Rik, PPDIV, PAIS, invasive procedures, VAL, HSGA, vp165, Angioplasty, nat5, Gamma-seminoprotein, Balearic Islands, Targeted Radiation Therapy, experimental, PSACH, Autoimmune Disease, MPS, Races, fas, mucoepidermoid tumours, Xt, Deoxyribonucleic acids, Surrogate End Points, CD95, Mitomycin, Investigative, III, Homo sapiens, Miquelon and St. Pierre, Studies, Mass, Tobacco, R9-29, DmF2, A-10, CG9579, IRAP, MRC, 90 kDa N-WASP-interacting protein, study, PROS, localized, lip-pit syndrome, hypopituitarism, Research, entire lifespan, experimental section, Biological Marker, Munc-13, mental deficiency, mammary part of chest, synthetic genetic interaction defined by inequality, Case-Control Study, EC6, Population Register, International Committee of the Red Cross, Examination, and postaxial polydactyly, Infestation and Infection, Sardinia, Scholarships, Immunologic Markers, time of survival, Proteus <enterobacteria>, Clients, disorder, HIGM2, red cell hypoplasia, toxic potential, DmelCG34358, G[[oalpha]], Family, Prostatectomy, DGalpha0, PRR6, Controlling, CO-methylating acetyl-coenzyme A synthase activity, PAPB, myocardial infarction, PAPA, selD/sps1, RnBP, RPTP-LAR, preinitiation complex, Targeted, Great Britain, Ethnic Groups, l(3)11m-254, Pallister Hall syndrome, medical condition, l(1)G0293, Historical Aspect, MUG, PS24, ACECS, PS23, ptuf, PS25, short-chain acyl-coenzyme A synthetase activity, PS22, survival, PS21, peroperative procedures, Infection, Bamacan, hNKR-P1A, Medical Transcription, Continental, ds-DNA, specimen collection, Data Base, Matched Case Control Studies, MOPD2, Radiations, immune system disease or disorder, acute, Fetuin-A, Serum Marker, PARA, PARC, neuroaxonal dystrophy presenting with neonatal dysmorphic features, ARA24, Myocardial Infarctions, Normality, Experimental Medicine, PARK, 0203/10, Risks, PPRibP, DCD-1, acetyl CoA ligase activity, patient, FLO10, Suprapubic Prostatectomies, EAST, san, Fetal Alcohol Syndrome, PPP1R68, Therapeutic, Dei, Case Comparison Studies, Acas, Acute Chest Syndrome, Acap, CG8271, l(3)L3, PHACS, perioperative procedures, neuroserpin, Other specified disorders of the immune mechanism, Treatment, fasII, INFARCTION (MI), Acoustic Wave, D18Ertd451e, Summary, Serums, sbl, PRSI, GCPS, Stocks, LFIS, Surrogate Endpoints, Black, acetylglucosaminyltransferase-like protein, dhc64C, Lactiferous gland, Consent, bas, fs(1)M34, FLORAL ORGAN NUMBER 1, End-Of-Life, beta-cat, Relative, Dunc-13, cDC, Health Diaries, Sound, INAD, dhc64c, CDA2, symptoms, AAP, cDhc64C, l(2)31Eh, IRIS, CG4601, Ethnic Group, AMAC-1, Galpha47A, Transluminal Angioplasty, PAST, CG5939, su(w[sp]), DFNX1, DmelCG8553, Dhc, Priorities, imprinted and ancient gene protein, Galphao47A, 2310065E01Rik, thymus nucleic acid, Case-Referrent Studies, 1.1.1.95, Biopsies, Autoimmune disease, PAPA1, Progress Report, CMTDIC, Literacy, CHIP, CG18572, General Internal Medicine, Mbp-1, Age of onset, kendrin, Tac3r, NLS2, Afro Americans, Yrs, and prominent incisors, Community Health, Case-Compeer, Upper, ACE, set, medicine, sample, CDC2, fas-II, RED, ACS, ACT, HPAST1, 6.3.2.6, Spi17, Nested Case Control Studies, DmAAF34715, RNF100, Parish Register, University Hospitals, preventive therapy, Viral, Myocardial Infarcts, shB, Advertisements, VND, Tnfrsf6, Ddb1, familial, ACs, CDCP, Puncture Biopsy, anon-85Ab, Victoria <flowering plants>, ms(3)neo30, Questionnaire Design, Collections, Subjects, digit, AEC, DmelCG4157, Ametycine, Myocardial infarction NOS, DIP-1, fas II, Heterologous Insemination, MTDPS4A, Joubert syndrome 12/15, desoxyribose nucleic acid, END, hereditary late-onset Parkinson disease, little, fg, Dmel_CG6393, with deafness and loss of vision, African Americans, Seitelberger disease, SH3 adapter protein SPIN90, mAb 1D4, maleate, 0106/05, content, follow up, cDhc, signs, Dhc64, Researcher, EG:86E4.6, BLyS, CG107278, AGE, experimental procedures, Urine, OTTMUSG00000001265, living, Agency, Computerized Medical Record, PIG44, and absence of corpus callosum, Material, Financial Activities, HMW MAP, DCAP, SPIN90, Preventive Medicine & Public Health, Public Health Service, 3-(N-phenylacetylamino)-2, Continental Population, Phospholipase A2-associated neurodegeneration, E430016J11Rik, Infarction, 1366/03, Elderly, l(1)Ab, RNF53, Fas 2, whole exome, X-linked, AI837402, Endoluminal, AHS, Clinical Marker, CLEC5B, Insurance Premium, dran, Kingdom of the Netherlands, Surgery, Forested Areas, PLA2G6 neurodegeneration with brain iron accumulation, PSA levels, NAT13P, Nk3r, Private, acyl-activating enzyme activity, AID, Biomedical, l(1)GA100, DmelCG6775, BAFF, DmelCG9802, DmelCG5441, Cardiac, Medical Specialities, drogpad, Congo (Brazzaville), SD01679, Girls, SMC protein 3, DG[[o]], synthetic genetic interaction (sensu inequality), Antemortem, Documents, nat13, cataract X-linked with Hutchinsonian teeth, Aland Islands, Man, bkh, Normalities, Community Financing, Insemination, l(3)04322, Transcription, positional, CAP1-PEN, Case-Referent, 142926_at, occurrence, TAKR86C, Disorders involving the immune mechanism, dRpn12, PSAT, autosomal dominant late-onset Parkinson disease, Case Control Studies, Sciences, Long-Term, E(zen)3, l(1)GA122, fs(1)829, Paradichlorbenzol, CD161, Cspg6, Dmel_CG32508, Canis rufus, Nationality, CG42257, Dmel_CG30327, Investigational Medicine, snp, Guernsey Island, Insurance, CDK1, constitutitional genetic, DmelCG10728, pure red cell aplasia, Cancer, Drl, hereditary prostate cancer, Antemortem Diagnoses, DmelCG4561, RAD3D, ALR, LcpIII, whole blood, Women Groups, PSCP, intraoperative procedures, synthetic DNA, TALL1, 3PGDH, Fellowships, TALL2, DmNa[[v]], AMI, Mdu, Human Donor, l(1)arm, N-acetyl-D-glucosamine 2-epimerase, RP3-330M21.2, TYRRS, 93Bal, Surrogate End Point, ROK, Neoplasm, Pcbd, m239Asp, synthetic, vnd/NK-2, VWS, Donor, DC-CK1, HSP28, HSP27, Men, S14, Disorder of the immune mechanism NOS (disorder), outbreaks, twelfth cranial nerve, Survey Personnel, 5363, primary cancer, postaxial polydactyly, AKAP, storage, Endpoints, ms(3)61CD, CG4216, Cancers, NHS, disease of immune system, CG9907, Longterm Effects, CG11579, immune disease, DmelCG5861, NaCh6, Infarctions, Reports, control, Radiation Therapy, tumors, Urologist, mAb1D4, DmHsp27, CG2043, EG:133E12.4, Diaphanous protein-interacting protein, hereditary, l(3)XIIm137, API, AF3P21, pm, AI266894, Registered, MAK3, Immune Markers, WASLBP, m275Asp, APS, beta-cat-arm, Antemortem Diagnosis, United States National Program of Cancer Registries, l(3)05592, AU023367, determination, postnatal development, Mbp1, atado, NK2, Repairs, pre-integration complex, CG4157, check-up, composed of, csp2, Continental Population Groups, AI451642, CG11121, anon-EST:Posey261, BANK, DmelCG3665, ranGap, NKD, old, hereditary late onset Parkinson disease, diseases, Internal Medicine, DmelCG1007, SAICAR synthetase, T16B5.15, United States. Public Health Service, diseases and disorders, NKR, preoperative procedures, Effect, U4|U6.U5 snRNP 27 kDa protein, 2310040B03Rik, ARM, Matched Case-Control Study, Family Life Cycle, Donor Artificial, DmelCG42257, bss, Insurance Medicine, metastatic prostate carcinoma, Man (Taxonomy), reference sample, FACS, HCAP, [X]Disorder involving the immune mechanism, punc, Woodland, Records as Topics, Designs, CMTX5, NKr, ataxia, End Of Life, Questionnaires, Histories, EG:118B3.1, Travel Documents, sp, Galphao, GU mismatch-specific uracil-DNA glycosylase activity, preventive measures, Akap550, Progress, Prostatic Neoplasm, Retropubic Prostatectomies, Markers, hallux Duplication, malignant neoplasm, 12n, Malignancies, Double-Stranded DNA, deoxyribonucleic acids, Research Priority, Needle, Heart Attacks, l(1)RC24, Consultant, Myocardial infarction, br31, Dm UO, Upper Arms, Questionnaire, H7AP1, digit (phalangeal portion) plus soft tissue, Centers for Disease Control and Prevention National Program of Cancer Registries, DCOH, neuroaxonal dystrophy, l(1)G0336, frequency, Modern, LOPD, Lypla3, Case-Comparison Study, Public Hospital, Ponsin, Nat13, Biologic Marker, L[[3]]CP3, Girl, Programs, Advisory Services, Gray, Afro-American, Investigative Report, WASP-interacting SH3-domain protein, CG5061, CG6393, 162, l(1)EC6, DmCdc2, dDdb1, NOS, Hunter-Carpenter-McDonald syndrome, EG:EG0007.3, Peptidase inhibitor 6, General, dSmad4, region, Genetic Material, CERIII, Action, drok, dLdb, Risk, RY1, Death Cause, AI854843, life, cataract-dental syndrome, DmelCG9390, Exomes, Chromosome-associated polypeptide, Race, LARGE_HUMAN, morbidity, goalpha, BRCA2 Gene, amphoterin, Health, HCE1, CG8553, t12687 ALR Dm, Registry, C19orf17, Horka, AW536573, Subject, ALDR1, Travel, Fs(3)Horka, microarray, Nucleic acid-binding protein RY-1, Cistron, l(3)S136603, DmelCG11579, MART, mGSTT2, multiple endocrine neoplasia syndrome(s), IMMUNE MECHANISM DIS NEC, FAS, Digital Rectal Examinations, Ag72H5, Hopefulness, Lysosomal phospholipase A2, mammary region, digit ( phalanges plus metapodial) plus soft tissue, CIAT, Palpations, Internal, Family Member, acetyl activating enzyme, dCHIP, BEST:GH28401, Specimen Collections, Gene, l(2)br31, Canis simensis, presence, Capt, froggy, selD, RanGAP, Rita, Review Committees, check up, DmelCG11121, DmelCG1404, nuclear DEIH-boxhelicase, heredity, Care, ALPHA-2-PI, IMMUNE MECHANISM DIS NOS, anon-WO0140519.210, Polish People's Republic, Biomarker, hYAK3-2, Methodology, Other deficiency of cell-mediated immunity, somda, HEL-S-83p, R85FL, Insurance Premiums, CG5074, distribution, X-linked fatal ataxia with deafness and loss of vision, nervus hypoglossus [xii], Mesiodens cataract syndrome, acetyl CoA synthase activity, MSMBBP, Clinical Investigators, Cytosol alanyl aminopeptidase, Brachium, Targeted Radiotherapies, Human Subject, DmelCG7171, immune disorder, HSPC046, Ect5, non-neoplastic, Miquelon and Saint Pierre, SMAD4, SGPA, Electronic Health Record Data, Electronic, Personal Respect, Angioplasties, Nat5, site, acrocallosal syndrome, Republic of Uganda, UNC-13, Proteus <salamanders>, Kinship Networks, School Age Population, CRISP9, nervus hypoglossus, delilah, Computerized Medical Records, PTGHS, CT12301, Task Force, Disease, ng/ml, Edg, Males, American Cancer Societies, Investigator, 59 kDa bone sialic acid-containing protein, GlcNAc 2-epimerase, End Point, Non Tobacco Products, artificial gene, l(3)S047110, prostate cancer metastatic, 3.4.11.14, Cistrons, impact-a, gsp1, obesity, development, tc4, TNF- and APOL-related leukocyte expressed ligand 2, STL5, Examinations, hK3, core, PNUTL2, DmCdk1, Corsica, Methods, age of onset, Community Surveys, SAN, Data Administration, G-alpha-47A, l(3)85Ac, 153636_at, AceCS, Rest, cap, Aspiration Biopsy, synthetic constructs, progressive cerebral poliodystrophy, alpha(o), Surrogate Marker, Prostate Neoplasm, United States Centers for Disease Control, autoimmune diseases, WBS15, American Red Cross, dLDB/Chip, Whites, Management, BAM, cardinality, African, Macedonia (Greece), assay, 0094/26, Malay Peninsula, groupe, RWDD5, Solo Practices, RanfalseOncoArray: Prostate CancerOriginal description of the study: From ELLIPSE (linked to the PRACTICAL consortium), we contributed ~78,000 SNPs to the OncoArray. A large fraction of the content was derived from the GWAS meta-analyses in European ancestry populations (overall and aggressive disease; ~27K SNPs). We also selected just over 10,000 SNPs from the meta-analyses in the non-European populations, with a majority of these SNPs coming from the analysis of overall prostate cancer in African ancestry populations as well as from the multiethnic meta-analysis. A substantial fraction of SNPs (~28,000) were also selected for fine-mapping of 53 loci not included in the common fine-mapping regions (tagging at r2>0.9 across ±500kb regions). We also selected a few thousand SNPs related with PSA levels and/or disease survival as well as SNPs from candidate lists provided by study collaborators, as well as from meta-analyses of exome SNP chip data from the Multiethnic Cohort and UK studies. The Contributing Studies: Aarhus: Hospital-based, Retrospective, Observational. Source of cases: Patients treated for prostate adenocarcinoma at Department of Urology, Aarhus University Hospital, Skejby (Aarhus, Denmark). Source of controls: Age-matched males treated for myocardial infarction or undergoing coronary angioplasty, but with no prostate cancer diagnosis based on information retrieved from the Danish Cancer Register and the Danish Cause of Death Register. AHS: Nested case-control study within prospective cohort. Source of cases: linkage to cancer registries in study states. Source of controls: matched controls from cohort ATBC: Prospective, nested case-control. Source of cases: Finnish male smokers aged 50-69 years at baseline. Source of controls: Finnish male smokers aged 50-69 years at baseline BioVu: Cases identified in a biobank linked to electronic health records. Source of cases: A total of 214 cases were identified in the VUMC de-identified electronic health records database (the Synthetic Derivative) and shipped to USC for genotyping in April 2014. The following criteria were used to identify cases: Age 18 or greater; male; African Americans (Black) only. Note that African ancestry is not self-identified, it is administratively or third-party assigned (which has been shown to be highly correlated with genetic ancestry for African Americans in BioVU; see references). Source of controls: Controls were identified in the de-identified electronic health record. Unfortunately, they were not age matched to the cases, and therefore cannot be used for this study. Canary PASS: Prospective, Multi-site, Observational Active Surveillance Study. Source of cases: clinic based from Beth Israel Deaconness Medical Center, Eastern Virginia Medical School, University of California at San Francisco, University of Texas Health Sciences Center San Antonio, University of Washington, VA Puget Sound. Source of controls: N/A CCI: Case series, Hospital-based. Source of cases: Cases identified through clinics at the Cross Cancer Institute. Source of controls: N/A CerePP French Prostate Cancer Case-Control Study (ProGene): Case-Control, Prospective, Observational, Hospital-based. Source of cases: Patients, treated in French departments of Urology, who had histologically confirmed prostate cancer. Source of controls: Controls were recruited as participating in a systematic health screening program and found unaffected (normal digital rectal examination and total PSA < 4 ng/ml, or negative biopsy if PSA > 4 ng/ml). COH: hospital-based cases and controls from outside. Source of cases: Consented prostate cancer cases at City of Hope. Source of controls: Consented unaffected males that were part of other studies where they consented to have their DNA used for other research studies. COSM: Population-based cohort. Source of cases: General population. Source of controls: General population CPCS1: Case-control - Denmark. Source of cases: Hospital referrals. Source of controls: Copenhagen General Population Study CPCS2: Source of cases: Hospital referrals. Source of controls: Copenhagen General Population Study CPDR: Retrospective cohort. Source of cases: Walter Reed National Military Medical Center. Source of controls: Walter Reed National Military Medical Center ACS_CPS-II: Nested case-control derived from a prospective cohort study. Source of cases: Identified through self-report on follow-up questionnaires and verified through medical records or cancer registries, identified through cancer registries or the National Death Index (with prostate cancer as the primary cause of death). Source of controls: Cohort participants who were cancer-free at the time of diagnosis of the matched case, also matched on age (±6 mo) and date of biospecimen donation (±6 mo). EPIC: Case-control - Germany, Greece, Italy, Netherlands, Spain, Sweden, UK. Source of cases: Identified through record linkage with population-based cancer registries in Italy, the Netherlands, Spain, Sweden and UK. In Germany and Greece, follow-up is active and achieved through checks of insurance records and cancer and pathology registries as well as via self-reported questionnaires; self-reported incident cancers are verified through medical records. Source of controls: Cohort participants without a diagnosis of cancer EPICAP: Case-control, Population-based, ages less than 75 years at diagnosis, Hérault, France. Source of cases: Prostate cancer cases in all public hospitals and private urology clinics of département of Hérault in France. Cases validation by the Hérault Cancer Registry. Source of controls: Population-based controls, frequency age matched (5-year groups). Quotas by socio-economic status (SES) in order to obtain a distribution by SES among controls identical to the SES distribution among general population men, conditionally to age. ERSPC: Population-based randomized trial. Source of cases: Men with PrCa from screening arm ERSPC Rotterdam. Source of controls: Men without PrCa from screening arm ERSPC Rotterdam ESTHER: Case-control, Prospective, Observational, Population-based. Source of cases: Prostate cancer cases in all hospitals in the state of Saarland, from 2001-2003. Source of controls: Random sample of participants from routine health check-up in Saarland, in 2000-2002 FHCRC: Population-based, case-control, ages 35-74 years at diagnosis, King County, WA, USA. Source of cases: Identified through the Seattle-Puget Sound SEER cancer registry. Source of controls: Randomly selected, age-frequency matched residents from the same county as cases Gene-PARE: Hospital-based. Source of cases: Patients that received radiotherapy for treatment of prostate cancer. Source of controls: n/a Hamburg-Zagreb: Hospital-based, Prospective. Source of cases: Prostate cancer cases seen at the Department of Oncology, University Hospital Center Zagreb, Croatia. Source of controls: Population-based (Croatia), healthy men, older than 50, with no medical record of cancer, and no family history of cancer (1st & 2nd degree relatives) HPFS: Nested case-control. Source of cases: Participants of the HPFS cohort. Source of controls: Participants of the HPFS cohort IMPACT: Observational. Source of cases: Carriers and non-carriers (with a known mutation in the family) of the BRCA1 and BRCA2 genes, aged between 40 and 69, who are undergoing prostate screening with annual PSA testing. This cohort has been diagnosed with prostate cancer during the study. Source of controls: Carriers and non-carriers (with a known mutation in the family) of the BRCA1 and BRCA2 genes, aged between 40 and 69, who are undergoing prostate screening with annual PSA testing. This cohort has not been diagnosed with prostate cancer during the study. IPO-Porto: Hospital-based. Source of cases: Early onset and/or familial prostate cancer. Source of controls: Blood donors Karuprostate: Case-control, Retrospective, Population-based. Source of cases: From FWI (Guadeloupe): 237 consecutive incident patients with histologically confirmed prostate cancer attending public and private urology clinics; From Democratic Republic of Congo: 148 consecutive incident patients with histologically confirmed prostate cancer attending the University Clinic of Kinshasa. Source of controls: From FWI (Guadeloupe): 277 controls recruited from men participating in a free systematic health screening program open to the general population; From Democratic Republic of Congo: 134 controls recruited from subjects attending the University Clinic of Kinshasa KULEUVEN: Hospital-based, Prospective, Observational. Source of cases: Prostate cancer cases recruited at the University Hospital Leuven. Source of controls: Healthy males with no history of prostate cancer recruited at the University Hospitals, Leuven. LAAPC: Subjects were participants in a population-based case-control study of aggressive prostate cancer conducted in Los Angeles County. Cases were identified through the Los Angeles County Cancer Surveillance Program rapid case ascertainment system. Eligible cases included African American, Hispanic, and non-Hispanic White men diagnosed with a first primary prostate cancer between January 1, 1999 and December 31, 2003. Eligible cases also had (a) prostatectomy with documented tumor extension outside the prostate, (b) metastatic prostate cancer in sites other than prostate, (c) needle biopsy of the prostate with Gleason grade ≥8, or (d) needle biopsy with Gleason grade 7 and tumor in more than two thirds of the biopsy cores. Eligible controls were men never diagnosed with prostate cancer, living in the same neighborhood as a case, and were frequency matched to cases on age (± 5 y) and race/ethnicity. Controls were identified by a neighborhood walk algorithm, which proceeds through an obligatory sequence of adjacent houses or residential units beginning at a specific residence that has a specific geographic relationship to the residence where the case lived at diagnosis. Malaysia: Case-control. Source of cases: Patients attended the outpatient urology or uro-onco clinic at University Malaya Medical Center. Source of controls: Population-based, age matched (5-year groups), ascertained through electoral register, Subang Jaya, Selangor, Malaysia MCC-Spain: Case-control. Source of cases: Identified through the urology departments of the participating hospitals. Source of controls: Population-based, frequency age and region matched, ascertained through the rosters of the primary health care centers MCCS: Nested case-control, Melbourne, Victoria. Source of cases: Identified by linkage to the Victorian Cancer Registry. Source of controls: Cohort participants without a diagnosis of cancer MD Anderson: Participants in this study were identified from epidemiological prostate cancer studies conducted at the University of Texas MD Anderson Cancer Center in the Houston Metropolitan area. Cases were accrued in the Houston Medical Center and were not restricted with respect to Gleason score, stage or PSA. Controls were identified via random-digit-dialing or among hospital visitors and they were frequency matched to cases on age and race. Lifestyle, demographic, and family history data were collected using a standardized questionnaire. MDACC_AS: A prospective cohort study. Source of cases: Men with clinically organ-confined prostate cancer meeting eligibility criteria for a prospective cohort study of active surveillance at MD Anderson Cancer Center. Source of controls: N/A MEC: The Multiethnic Cohort (MEC) is comprised of over 215,000 men and women recruited from Hawaii and the Los Angeles area between 1993 and 1996. Between 1995 and 2006, over 65,000 blood samples were collected from participants for genetic analyses. To identify incident cancer cases, the MEC was cross-linked with the population-based Surveillance, Epidemiology and End Results (SEER) registries in California and Hawaii, and unaffected cohort participants with blood samples were selected as controls MIAMI (WFPCS): Prostate cancer cases and controls were recruited from the Departments of Urology and Internal Medicine of the Wake Forest University School of Medicine using sequential patient populations as described previously (<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=+15342424">PMID:15342424</a>). All study subjects received a detailed description of the study protocol and signed their informed consent, as approved by the medical center's Institutional Review Board. The general eligibility criteria were (i) able to comprehend informed consent and (ii) without previously diagnosed cancer. The exclusion criteria were (i) clinical diagnosis of autoimmune diseases; (ii) chronic inflammatory conditions; and (iii) infections within the past 6 weeks. Blood samples were collected from all subjects. MOFFITT: Hospital-based. Source of cases: clinic based from Moffitt Cancer Center. Source of controls: Moffitt Cancer Center affiliated Lifetime cancer screening center NMHS: Case-control, clinic based, Nashville TN. Source of cases: All urology clinics in Nashville, TN. Source of controls: Men without prostate cancer at prostate biopsy. PCaP: The North Carolina-Louisiana Prostate Cancer Project (PCaP) is a multidisciplinary population-based case-only study designed to address racial differences in prostate cancer through a comprehensive evaluation of social, individual and tumor level influences on prostate cancer aggressiveness. PCaP enrolled approximately equal numbers of African Americans and Caucasian Americans with newly-diagnosed prostate cancer from North Carolina (42 counties) and Louisiana (30 parishes) identified through state tumor registries. African American PCaP subjects with DNA, who agreed to future use of specimens for research, participated in OncoArray analysis. PCMUS: Case-control - Sofia, Bulgaria. Source of cases: Patients of Clinic of Urology, Alexandrovska University Hospital, Sofia, Bulgaria, PrCa histopathologically confirmed. Source of controls: 72 patients with verified BPH and PSA<3,5; 78 healthy controls from the MMC Biobank, no history of PrCa PHS: Nested case-control. Source of cases: Participants of the PHS1 trial/cohort. Source of controls: Participants of the PHS1 trial/cohort PLCO: Nested case-control. Source of cases: Men with a confirmed diagnosis of prostate cancer from the PLCO Cancer Screening Trial. Source of controls: Controls were men enrolled in the PLCO Cancer Screening Trial without a diagnosis of cancer at the time of case ascertainment. Poland: Case-control. Source of cases: men with unselected prostate cancer, diagnosed in north-western Poland at the University Hospital in Szczecin. Source of controls: cancer-free men from the same population, taken from the healthy adult patients of family doctors in the Szczecin region PROCAP: Population-based, Retrospective, Observational. Source of cases: Cases were ascertained from the National Prostate Cancer Register of Sweden Follow-Up Study, a retrospective nationwide cohort study of patients with localized prostate cancer. Source of controls: Controls were selected among men referred for PSA testing in laboratories in Stockholm County, Sweden, between 2010 and 2012. PROGReSS: Hospital-based, Prospective, Observational. Source of cases: Prostate cancer cases from the Hospital Clínico Universitario de Santiago de Compostela, Galicia, Spain. Source of controls: Cancer-free men from the same population ProMPT: A study to collect samples and data from subjects with and without prostate cancer. Retrospective, Experimental. Source of cases: Subjects attending outpatient clinics in hospitals. Source of controls: Subjects attending outpatient clinics in hospitals ProtecT: Trial of treatment. Samples taken from subjects invited for PSA testing from the community at nine centers across United Kingdom. Source of cases: Subjects who have a proven diagnosis of prostate cancer following testing. Source of controls: Identified through invitation of subjects in the community. PROtEuS: Case-control, population-based. Source of cases: All new histologically-confirmed cases, aged less or equal to 75 years, diagnosed between 2005 and 2009, actively ascertained across Montreal French hospitals. Source of controls: Randomly selected from the Provincial electoral list of French-speaking men between 2005 and 2009, from the same area of residence as cases and frequency-matched on age. QLD: Case-control. Source of cases: A longitudinal cohort study (Prostate Cancer Supportive Care and Patient Outcomes Project: ProsCan) conducted in Queensland, through which men newly diagnosed with prostate cancer from 26 private practices and 10 public hospitals were directly referred to ProsCan at the time of diagnosis by their treating clinician (age range 43-88 years). All cases had histopathologically confirmed prostate cancer, following presentation with an abnormal serum PSA and/or lower urinary tract symptoms. Source of controls: Controls comprised healthy male blood donors with no personal history of prostate cancer, recruited through (i) the Australian Red Cross Blood Services in Brisbane (age range 19-76 years) and (ii) the Australian Electoral Commission (AEC) (age and post-code/ area matched to ProsCan, age range 54-90 years). RAPPER: Multi-centre, hospital based blood sample collection study in patients enrolled in clinical trials with prospective collection of radiotherapy toxicity data. Source of cases: Prostate cancer patients enrolled in radiotherapy trials: CHHiP, RT01, Dose Escalation, RADICALS, Pelvic IMRT, PIVOTAL. Source of controls: N/A SABOR: Prostate Cancer Screening Cohort. Source of cases: Men >45 yrs of age participating in annual PSA screening. Source of controls: Males participating in annual PSA prostate cancer risk evaluations (funded by NCI biomarkers discovery and validation grant), recruited through University of Texas Health Science Center at San Antonio and affiliated sites or through study advertisements, enrolment open to the community SCCS: Case-control in cohort, Southeastern USA. Prospective, Observational, Population-based. Source of cases: SCCS entry population. Source of controls: SCCS entry population SCPCS: Population-based, Retrospective, Observational. Source of cases: South Carolina Central Cancer Registry. Source of controls: Health Care Financing Administration beneficiary file SEARCH: Case-control - East Anglia, UK. Source of cases: Men < 70 years of age registered with prostate cancer at the population-based cancer registry, Eastern Cancer Registration and Information Centre, East Anglia, UK. Source of controls: Men attending general practice in East Anglia with no known prostate cancer diagnosis, frequency matched to cases by age and geographic region SNP_Prostate_Ghent: Hospital-based, Retrospective, Observational. Source of cases: Men treated with IMRT as primary or postoperative treatment for prostate cancer at the Ghent University Hospital between 2000 and 2010. Source of controls: Employees of the University hospital and members of social activity clubs, without a history of any cancer. SPAG: Hospital-based, Retrospective, Observational. Source of cases: Guernsey. Source of controls: Guernsey STHM2: Population-based, Retrospective, Observational. Source of cases: Cases were selected among men referred for PSA testing in laboratories in Stockholm County, Sweden, between 2010 and 2012. Source of controls: Controls were selected among men referred for PSA testing in laboratories in Stockholm County, Sweden, between 2010 and 2012. PCPT: Case-control from a randomized clinical trial. Source of cases: Randomized clinical trial. Source of controls: Randomized clinical trial SELECT: Case-cohort from a randomized clinical trial. Source of cases: Randomized clinical trial. Source of controls: Randomized clinical trial TAMPERE: Case-control - Finland, Retrospective, Observational, Population-based. Source of cases: Identified through linkage to the Finnish Cancer Registry and patient records; and the Finnish arm of the ERSPC study. Source of controls: Cohort participants without a diagnosis of cancer UGANDA: Uganda Prostate Cancer Study: Uganda is a case-control study of prostate cancer in Kampala Uganda that was initiated in 2011. Men with prostate cancer were enrolled from the Urology unit at Mulago Hospital and men without prostate cancer (i.e. controls) were enrolled from other clinics (i.e. surgery) at the hospital. UKGPCS: ICR, UK. Source of cases: Cases identified through clinics at the Royal Marsden hospital and nationwide NCRN hospitals. Source of controls: Ken Muir's control- 2000 ULM: Case-control - Germany. Source of cases: familial cases (n=162): identified through questionnaires for family history by collaborating urologists all over Germany; sporadic cases (n=308): prostatectomy series performed in the Clinic of Urology Ulm between 2012 and 2014. Source of controls: age-matched controls (n=188): age-matched men without prostate cancer and negative family history collected in hospitals of Ulm WUGS/WUPCS: Cases Series, USA. Source of cases: Identified through clinics at Washington University in St. Louis. Source of controls: Men diagnosed and managed with prostate cancer in University based clinic. Acknowledgement Statements: Aarhus: This study was supported by the Danish Strategic Research Council (now Innovation Fund Denmark) and the Danish Cancer Society. The Danish Cancer Biobank (DCB) is acknowledged for biological material. AHS: This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics (Z01CP010119). ATBC: This research was supported in part by the Intramural Research Program of the NIH and the National Cancer Institute. Additionally, this research was supported by U.S. Public Health Service contracts N01-CN-45165, N01-RC-45035, N01-RC-37004, HHSN261201000006C, and HHSN261201500005C from the National Cancer Institute, Department of Health and Human Services. BioVu: The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by institutional funding and by the National Center for Research Resources, Grant UL1 RR024975-01 (which is now at the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06). Canary PASS: PASS was supported by Canary Foundation and the National Cancer Institute's Early Detection Research Network (U01 CA086402) CCI: This work was awarded by Prostate Cancer Canada and is proudly funded by the Movember Foundation - Grant # D2013-36.The CCI group would like to thank David Murray, Razmik Mirzayans, and April Scott for their contribution to this work. CerePP French Prostate Cancer Case-Control Study (ProGene): None reported COH: SLN is partially supported by the Morris and Horowitz Families Endowed Professorship COSM: The Swedish Research Council, the Swedish Cancer Foundation CPCS1 & CPCS2: Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev, DenmarkCPCS1 would like to thank the participants and staff of the Copenhagen General Population Study for their important contributions. CPDR: Uniformed Services University for the Health Sciences HU0001-10-2-0002 (PI: David G. McLeod, MD) CPS-II: The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study II cohort. CPS-II thanks the participants and Study Management Group for their invaluable contributions to this research. We would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. EPIC: The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); the Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation, Greek Ministry of Health; Greek Ministry of Education (Greece); the Italian Association for Research on Cancer (AIRC) and National Research Council (Italy); the Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF); the Statistics Netherlands (The Netherlands); the Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, Spanish Ministry of Health ISCIII RETIC (RD06/0020), Red de Centros RCESP, C03/09 (Spain); the Swedish Cancer Society, Swedish Scientific Council and Regional Government of Skåne and Västerbotten, Fundacion Federico SA (Sweden); the Cancer Research UK, Medical Research Council (United Kingdom). EPICAP: The EPICAP study was supported by grants from Ligue Nationale Contre le Cancer, Ligue départementale du Val de Marne; Fondation de France; Agence Nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES). The EPICAP study group would like to thank all urologists, Antoinette Anger and Hasina Randrianasolo (study monitors), Anne-Laure Astolfi, Coline Bernard, Oriane Noyer, Marie-Hélène De Campo, Sandrine Margaroline, Louise N'Diaye, and Sabine Perrier-Bonnet (Clinical Research nurses). ERSPC: This study was supported by the DutchCancerSociety (KWF94-869,98-1657,2002-277,2006-3518, 2010-4800), The Netherlands Organisation for Health Research and Development (ZonMW-002822820, 22000106, 50-50110-98-311, 62300035), The Dutch Cancer Research Foundation (SWOP), and an unconditional grant from Beckman-Coulter-HybritechInc. ESTHER: The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. The ESTHER group would like to thank Hartwig Ziegler, Sonja Wolf, Volker Hermann, Heiko Müller, Karina Dieffenbach, Katja Butterbach for valuable contributions to the study. FHCRC: The FHCRC studies were supported by grants R01-CA056678, R01-CA082664, and R01-CA092579 from the US National Cancer Institute, National Institutes of Health, with additional support from the Fred Hutchinson Cancer Research Center. FHCRC would like to thank all the men who participated in these studies. Gene-PARE: The Gene-PARE study was supported by grants 1R01CA134444 from the U.S. National Institutes of Health, PC074201 and W81XWH-15-1-0680 from the Prostate Cancer Research Program of the Department of Defense and RSGT-05-200-01-CCE from the American Cancer Society. Hamburg-Zagreb: None reported HPFS: The Health Professionals Follow-up Study was supported by grants UM1CA167552, CA133891, CA141298, and P01CA055075. HPFS are grateful to the participants and staff of the Physicians' Health Study and Health Professionals Follow-Up Study for their valuable contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. IMPACT: The IMPACT study was funded by The Ronald and Rita McAulay Foundation, CR-UK Project grant (C5047/A1232), Cancer Australia, AICR Netherlands A10-0227, Cancer Australia and Cancer Council Tasmania, NIHR, EU Framework 6, Cancer Councils of Victoria and South Australia, and Philanthropic donation to Northshore University Health System. We acknowledge support from the National Institute for Health Research (NIHR) to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden Foundation NHS Trust. IMPACT acknowledges the IMPACT study steering committee, collaborating centres, and participants. IPO-Porto: The IPO-Porto study was funded by Fundaçäo para a Ciência e a Tecnologia (FCT; UID/DTP/00776/2013 and PTDC/DTP-PIC/1308/2014) and by IPO-Porto Research Center (CI-IPOP-16-2012 and CI-IPOP-24-2015). MC and MPS are research fellows from Liga Portuguesa Contra o Cancro, Núcleo Regional do Norte. SM is a research fellow from FCT (SFRH/BD/71397/2010). IPO-Porto would like to express our gratitude to all patients and families who have participated in this study. Karuprostate: The Karuprostate study was supported by the the Frech National Health Directorate and by the Association pour la Recherche sur les Tumeurs de la ProstateKarusprostate thanks Séverine Ferdinand. KULEUVEN: F.C. and S.J. are holders of grants from FWO Vlaanderen (G.0684.12N and G.0830.13N), the Belgian federal government (National Cancer Plan KPC_29_023), and a Concerted Research Action of the KU Leuven (GOA/15/017). TVDB is holder of a doctoral fellowship of the FWO. LAAPC: This study was funded by grant R01CA84979 (to S.A. Ingles) from the National Cancer Institute, National Institutes of Health. Malaysia: The study was funded by the University Malaya High Impact Research Grant (HIR/MOHE/MED/35). Malaysia thanks all associates in the Urology Unit, University of Malaya, Cancer Research Initiatives Foundation (CARIF) and the Malaysian Men's Health Initiative (MMHI). MCCS: MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553, and 504711, and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. MCC-Spain: The study was partially funded by the Accion Transversal del Cancer, approved on the Spanish Ministry Council on the 11th October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI09/00773-Cantabria, PI11/01889-FEDER, PI12/00265, PI12/01270, and PI12/00715), by the Fundación Marqués de Valdecilla (API 10/09), by the Spanish Association Against Cancer (AECC) Scientific Foundation and by the Catalan Government DURSI grant 2009SGR1489. Samples: Biological samples were stored at the Parc de Salut MAR Biobank (MARBiobanc; Barcelona) which is supported by Instituto de Salud Carlos III FEDER (RD09/0076/00036). Also sample collection was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d'Oncologia de Catalunya (XBTC). MCC-Spain acknowledges the contribution from Esther Gracia-Lavedan in preparing the data. We thank all the subjects who participated in the study and all MCC-Spain collaborators. MD Anderson: Prostate Cancer Case-Control Studies at MD Anderson (MDA) supported by grants CA68578, ES007784, DAMD W81XWH-07-1-0645, and CA140388. MDACC_AS: None reported MEC: Funding provided by NIH grant U19CA148537 and grant U01CA164973. MIAMI (WFPCS): ACS MOFFITT: The Moffitt group was supported by the US National Cancer Institute (R01CA128813, PI: J.Y. Park). NMHS: Funding for the Nashville Men's Health Study (NMHS) was provided by the National Institutes of Health Grant numbers: RO1CA121060. PCaP only data: The North Carolina - Louisiana Prostate Cancer Project (PCaP) is carried out as a collaborative study supported by the Department of Defense contract DAMD 17-03-2-0052. For HCaP-NC follow-up data: The Health Care Access and Prostate Cancer Treatment in North Carolina (HCaP-NC) study is carried out as a collaborative study supported by the American Cancer Society award RSGT-08-008-01-CPHPS. For studies using both PCaP and HCaP-NC follow-up data please use: The North Carolina - Louisiana Prostate Cancer Project (PCaP) and the Health Care Access and Prostate Cancer Treatment in North Carolina (HCaP-NC) study are carried out as collaborative studies supported by the Department of Defense contract DAMD 17-03-2-0052 and the American Cancer Society award RSGT-08-008-01-CPHPS, respectively. For any PCaP data, please include: The authors thank the staff, advisory committees and research subjects participating in the PCaP study for their important contributions. For studies using PCaP DNA/genotyping data, please include: We would like to acknowledge the UNC BioSpecimen Facility and LSUHSC Pathology Lab for our DNA extractions, blood processing, storage and sample disbursement (<a href="https://genome.unc.edu/bsp">https://genome.unc.edu/bsp</a>). For studies using PCaP tissue, please include: We would like to acknowledge the RPCI Department of Urology Tissue Microarray and Immunoanalysis Core for our tissue processing, storage and sample disbursement. For studies using HCaP-NC follow-up data, please use: The Health Care Access and Prostate Cancer Treatment in North Carolina (HCaP-NC) study is carried out as a collaborative study supported by the American Cancer Society award RSGT-08-008-01-CPHPS. The authors thank the staff, advisory committees and research subjects participating in the HCaP-NC study for their important contributions. For studies that use both PCaP and HCaP-NC, please use: The authors thank the staff, advisory committees and research subjects participating in the PCaP and HCaP-NC studies for their important contributions. PCMUS: The PCMUS study was supported by the Bulgarian National Science Fund, Ministry of Education and Science (contract DOO-119/2009; DUNK01/2-2009; DFNI-B01/28/2012) with additional support from the Science Fund of Medical University - Sofia (contract 51/2009; 8I/2009; 28/2010). PHS: The Physicians' Health Study was supported by grants CA34944, CA40360, CA097193, HL26490, and HL34595. PHS members are grateful to the participants and staff of the Physicians' Health Study and Health Professionals Follow-Up Study for their valuable contributions, as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. PLCO: This PLCO study was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIHPLCO thanks Drs. Christine Berg and Philip Prorok, Division of Cancer Prevention at the National Cancer Institute, the screening center investigators and staff of the PLCO Cancer Screening Trial for their contributions to the PLCO Cancer Screening Trial. We thank Mr. Thomas Riley, Mr. Craig Williams, Mr. Matthew Moore, and Ms. Shannon Merkle at Information Management Services, Inc., for their management of the data and Ms. Barbara O'Brien and staff at Westat, Inc. for their contributions to the PLCO Cancer Screening Trial. We also thank the PLCO study participants for their contributions to making this study possible. Poland: None reported PROCAP: PROCAP was supported by the Swedish Cancer Foundation (08-708, 09-0677). PROCAP thanks and acknowledges all of the participants in the PROCAP study. We thank Carin Cavalli-Björkman and Ami Rönnberg Karlsson for their dedicated work in the collection of data. Michael Broms is acknowledged for his skilful work with the databases. KI Biobank is acknowledged for handling the samples and for DNA extraction. We acknowledge The NPCR steering group: Pär Stattin (chair), Anders Widmark, Stefan Karlsson, Magnus Törnblom, Jan Adolfsson, Anna Bill-Axelson, Ove Andrén, David Robinson, Bill Pettersson, Jonas Hugosson, Jan-Erik Damber, Ola Bratt, Göran Ahlgren, Lars Egevad, and Roy Ehrnström. PROGReSS: The PROGReSS study is founded by grants from the Spanish Ministry of Health (INT15/00070; INT16/00154; FIS PI10/00164, FIS PI13/02030; FIS PI16/00046); the Spanish Ministry of Economy and Competitiveness (PTA2014-10228-I), and Fondo Europeo de Desarrollo Regional (FEDER 2007-2013). ProMPT: Founded by CRUK, NIHR, MRC, Cambride Biomedical Research Centre ProtecT: Founded by NIHR. ProtecT and ProMPT would like to acknowledge the support of The University of Cambridge, Cancer Research UK. Cancer Research UK grants (C8197/A10123) and (C8197/A10865) supported the genotyping team. We would also like to acknowledge the support of the National Institute for Health Research which funds the Cambridge Bio-medical Research Centre, Cambridge, UK. We would also like to acknowledge the support of the National Cancer Research Prostate Cancer: Mechanisms of Progression and Treatment (PROMPT) collaborative (grant code G0500966/75466) which has funded tissue and urine collections in Cambridge. We are grateful to staff at the Welcome Trust Clinical Research Facility, Addenbrooke's Clinical Research Centre, Cambridge, UK for their help in conducting the ProtecT study. We also acknowledge the support of the NIHR Cambridge Biomedical Research Centre, the DOH HTA (ProtecT grant), and the NCRI/MRC (ProMPT grant) for help with the bio-repository. The UK Department of Health funded the ProtecT study through the NIHR Health Technology Assessment Programme (projects 96/20/06, 96/20/99). The ProtecT trial and its linked ProMPT and CAP (Comparison Arm for ProtecT) studies are supported by Department of Health, England; Cancer Research UK grant number C522/A8649, Medical Research Council of England grant number G0500966, ID 75466, and The NCRI, UK. The epidemiological data for ProtecT were generated though funding from the Southwest National Health Service Research and Development. DNA extraction in ProtecT was supported by USA Dept of Defense award W81XWH-04-1-0280, Yorkshire Cancer Research and Cancer Research UK. The authors would like to acknowledge the contribution of all members of the ProtecT study research group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health of England. The bio-repository from ProtecT is supported by the NCRI (ProMPT) Prostate Cancer Collaborative and the Cambridge BMRC grant from NIHR. We thank the National Institute for Health Research, Hutchison Whampoa Limited, the Human Research Tissue Bank (Addenbrooke's Hospital), and Cancer Research UK. PROtEuS: PROtEuS was supported financially through grants from the Canadian Cancer Society (13149, 19500, 19864, 19865) and the Cancer Research Society, in partnership with the Ministère de l'enseignement supérieur, de la recherche, de la science et de la technologie du Québec, and the Fonds de la recherche du Québec - Santé.PROtEuS would like to thank its collaborators and research personnel, and the urologists involved in subjects recruitment. We also wish to acknowledge the special contribution made by Ann Hsing and Anand Chokkalingam to the conception of the genetic component of PROtEuS. QLD: The QLD research is supported by The National Health and Medical Research Council (NHMRC) Australia Project Grants (390130, 1009458) and NHMRC Career Development Fellowship and Cancer Australia PdCCRS funding to J Batra. The QLD team would like to acknowledge and sincerely thank the urologists, pathologists, data managers and patient participants who have generously and altruistically supported the QLD cohort. RAPPER: RAPPER is funded by Cancer Research UK (C1094/A11728; C1094/A18504) and Experimental Cancer Medicine Centre funding (C1467/A7286). The RAPPER group thank Rebecca Elliott for project management. SABOR: The SABOR research is supported by NIH/NCI Early Detection Research Network, grant U01 CA0866402-12. Also supported by the Cancer Center Support Grant to the Cancer Therapy and Research Center from the National Cancer Institute (US) P30 CA054174. SCCS: SCCS is funded by NIH grant R01 CA092447, and SCCS sample preparation was conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485). Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry. SCPCS: SCPCS is funded by CDC grant S1135-19/19, and SCPCS sample preparation was conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485). SEARCH: SEARCH is funded by a program grant from Cancer Research UK (C490/A10124) and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. SNP_Prostate_Ghent: The study was supported by the National Cancer Plan, financed by the Federal Office of Health and Social Affairs, Belgium. SPAG: Wessex Medical ResearchHope for Guernsey, MUG, HSSD, MSG, Roger Allsopp STHM2: STHM2 was supported by grants from The Strategic Research Programme on Cancer (StratCan), Karolinska Institutet; the Linné Centre for Breast and Prostate Cancer (CRISP, number 70867901), Karolinska Institutet; The Swedish Research Council (number K2010-70X-20430-04-3) and The Swedish Cancer Society (numbers 11-0287 and 11-0624); Stiftelsen Johanna Hagstrand och Sigfrid Linnérs minne; Swedish Council for Working Life and Social Research (FAS), number 2012-0073STHM2 acknowledges the Karolinska University Laboratory, Aleris Medilab, Unilabs and the Regional Prostate Cancer Registry for performing analyses and help to retrieve data. Carin Cavalli-Björkman and Britt-Marie Hune for their enthusiastic work as research nurses. Astrid Björklund for skilful data management. We wish to thank the BBMRI.se biobank facility at Karolinska Institutet for biobank services. PCPT & SELECT are funded by Public Health Service grants U10CA37429 and 5UM1CA182883 from the National Cancer Institute. SWOG and SELECT thank the site investigators and staff and, most importantly, the participants who donated their time to this trial. TAMPERE: The Tampere (Finland) study was supported by the Academy of Finland (251074), The Finnish Cancer Organisations, Sigrid Juselius Foundation, and the Competitive Research Funding of the Tampere University Hospital (X51003). The PSA screening samples were collected by the Finnish part of ERSPC (European Study of Screening for Prostate Cancer). TAMPERE would like to thank Riina Liikanen, Liisa Maeaettaenen and Kirsi Talala for their work on samples and databases. UGANDA: None reported UKGPCS: UKGPCS would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. UKGPCS should also like to acknowledge the NCRN nurses, data managers, and consultants for their work in the UKGPCS study. UKGPCS would like to thank all urologists and other persons involved in the planning, coordination, and data collection of the study. ULM: The Ulm group received funds from the German Cancer Aid (Deutsche Krebshilfe). WUGS/WUPCS: WUGS would like to thank the following for funding support: The Anthony DeNovi Fund, the Donald C. McGraw Foundation, and the St. Louis Men's Group Against Cancer.2018-03-162017-06-23phs001391Prostatic Neoplasms